Tetrahedron p. 2385 - 2399 (2019)
Update date:2022-08-06
Topics:
Heckrodt, Thilo J.
Chen, Yan
Singh, Rajinder
An extensive medicinal chemistry campaign and subsequent SAR studies led to the discovery of the highly potent and selective JAK1/3 inhibitor R545. To support advanced pre-clinical DMPK studies of R545, the isotopically labeled versions of the drug and its metabolite R935 were required. Herein, we describe the development of synthetic routes to deuterium-labeled [D7]-R545 and its oxidative metabolite [D7]-R935. Deuterium atoms were introduced at several sites in the target molecules by employing a convergent synthesis strategy. The desired regiochemistry at the right-hand side of [D7]-R935 was established via a newly discovered protecting group-directed bromination. The described synthetic approach gave rise to the desired deuterium-labeled target compounds and sufficient quantities were synthesized to enable pre-clinical DMPK studies.
View MoreJIANGSU GRAND XINYI PHARMACEUTICAL CO.,LTD
website:http://www.xypharm.com/
Contact:+86-515-84383317
Address:Chenli Road,Costal Chemical Area Binhai,Yancheng, Jiangsu,China
Henan Allgreen Chemical Co.,Ltd
website:http://www.allgreenchem.com
Contact:+86-0371-87507775
Address:No 260 Dongming Road,Jinshui District
JIANGSU GRAND XINYI PHARMACEUTICAL CO.,LTD
website:http://www.xypharm.com/
Contact:+86-515-84383317
Address:Chenli Road,Costal Chemical Area Binhai,Yancheng, Jiangsu,China
Contact:86 311 85902108 / 85902109
Address:room 1001-1005 ,huanghe Road ,shijiazhuang ,China
Shaanxi HuaTai Bio-fine chemical company Ltd
Contact:86-029-87862197
Address:No. 5, 3rd Floor, 29 Yanta North Road, Beilin Dist.
Doi:10.1007/s10847-010-9742-3
(2011)Doi:10.1016/j.jfluchem.2011.03.005
(2012)Doi:10.1002/adsc.201100694
(2012)Doi:10.1021/ol300008d
(2012)Doi:10.1021/om00057a019
(1991)Doi:10.1016/j.bmc.2011.06.041
(2012)